{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:06:08Z","timestamp":1768277168430,"version":"3.49.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Reduction mammaplasty relieves symptomatic macromastia. Pathologic specimens occasionally reveal unsuspected proliferative lesions or carcinoma. Few studies examine the incidence, risk factors, and outcomes in this population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective review was performed between 2000 and 2012. The pathologic condition was categorized as benign, proliferative, or cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Five hundred seventy-two patients underwent 995 reduction mammaplasties. Cancer was detected in 23 specimens (2.3 percent) and proliferative lesions were detected in 137 (13.8 percent). Compared with patients with benign pathologic findings, patients with proliferative lesions or cancer were older (<jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001), had greater body mass index (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.003), had increased unilateral procedures (<jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001), and more had history of cancer (<jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001). On multivariable regression analysis, age (OR, 1.058; 95 percent CI, 1.040 to 1.077; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001) and prior breast cancer (OR, 2.070; 95 percent CI, 1.328 to 3.227, <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.001) were independent risk factors for proliferative lesions, and age significantly predicted cancer (OR, 1.054; 95 percent CI, 1.012 to 1.097; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.010). Forty-one percent of patients with proliferative lesions and no history of cancer had a change in management. If there was a history of cancer, 54 percent had a change in management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Proliferative lesions of the breast may be more common than previously reported. Age and a history of breast cancer increase the risk for proliferative lesions. All should be referred to oncology, as nearly half of these patients will have a change in management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL QUESTION\/LEVEL OF EVIDENCE:<\/jats:title>\n            <jats:p>Risk, III.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/prs.0000000000005192","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T19:48:48Z","timestamp":1543520928000},"page":"271e-275e","source":"Crossref","is-referenced-by-count":19,"title":["Proliferative Lesions Found at Reduction Mammaplasty: Incidence and Implications in 995 Breast Reductions"],"prefix":"10.1097","volume":"143","author":[{"given":"Melissa","family":"Mastroianni","sequence":"first","affiliation":[{"name":"From the Division of Plastic and Reconstructive Surgery and Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Lin","sequence":"additional","affiliation":[{"name":"From the Division of Plastic and Reconstructive Surgery and Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Hughes","sequence":"additional","affiliation":[{"name":"From the Division of Plastic and Reconstructive Surgery and Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy S.","family":"Colwell","sequence":"additional","affiliation":[{"name":"From the Division of Plastic and Reconstructive Surgery and Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20231017","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1097\/00006534-200204150-00011","article-title":"The effectiveness of surgical and nonsurgical interventions in relieving the symptoms of macromastia.","volume":"109","author":"Collins","year":"2002","journal-title":"Plast Reconstr Surg"},{"key":"R2-20231017","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1097\/01.PRS.0000122212.37703.6E","article-title":"Occult breast carcinoma in reduction mammaplasty specimens: 14-year experience.","volume":"113","author":"Colwell","year":"2004","journal-title":"Plast Reconstr Surg"},{"key":"R3-20231017","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJM198501173120303","article-title":"Risk factors for breast cancer in women with proliferative breast disease.","volume":"312","author":"Dupont","year":"1985","journal-title":"N Engl J Med"},{"key":"R4-20231017","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa044383","article-title":"Benign breast disease and the risk of breast cancer.","volume":"353","author":"Hartmann","year":"2005","journal-title":"N Engl J Med"},{"key":"R5-20231017","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/PRS.0b013e3181b988da","article-title":"Carcinoma and atypical hyperplasia in reduction mammaplasty: Increased sampling leads to increased detection. A prospective study.","volume":"124","author":"Ambaye","year":"2009","journal-title":"Plast Reconstr Surg"},{"key":"R6-20231017","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.humpath.2013.02.015","article-title":"Incidental atypical proliferative lesions in reduction mammoplasty specimens: Analysis of 2498 cases from 2 tertiary women\u2019s health centers.","volume":"44","author":"Desouki","year":"2013","journal-title":"Hum Pathol"},{"key":"R7-20231017","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.humpath.2013.08.010","article-title":"Incidental atypical proliferative lesions in reduction mammoplasty specimens in patients with a history of breast cancer.","volume":"45","author":"Li","year":"2014","journal-title":"Hum Pathol"},{"key":"R8-20231017","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2008.20.5179","article-title":"American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.","volume":"27","author":"Visvanathan","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006534-201902000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T10:26:21Z","timestamp":1697538381000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006534-201902000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/prs.0000000000005192","relation":{},"ISSN":["0032-1052"],"issn-type":[{"value":"0032-1052","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}